Table 1

Characteristics of patients with RA and patients without RA

RA (overall)Non-RARA (incident)Non-RA
N138 891138 89130 56230 562
Age, years55.6 (13.3)55.6 (13.3)54.5 (13.5)54.5 (13.5)
Female sex, %106 254 (76.5)106 254 (76.5)22 649 (74.1)22 649 (74.1)
Year of entry,* %
 200643 543 (31.4)43 543 (31.4)12 636 (41.4)12 636 (41.4)
 200711 858 (8.5)11 858 (8.5)2916 (9.5)2916 (9.5)
 200825 187 (18.1)25 187 (18.1)5903 (19.3)5903 (19.3)
 200917 284 (12.4)17 284 (12.4)3596 (11.8)3596 (11.8)
 201016 569 (11.9)16 569 (11.9)2994 (9.8)2994 (9.8)
 201111 624 (8.4)11 624 (8.4)1653 (5.4)1653 (5.4)
 20127589 (5.5)7589 (5.5)616 (2.0)616 (2.0)
 20135237 (3.8)5237 (3.8)248 (0.8)248 (0.8)
Time from entry to index date, years1.5 (1.7)1.5 (1.7)3.5 (1.8)3.5 (1.8)
US region, %
 Northeast23 393 (16.8)23 487 (16.9)4806 (15.7)4517 (14.8)
 North central29 559 (21.3)31 941 (23.0)6007 (19.7)6435 (21.1)
 South62 618 (45.1)53 884 (38.8)14 732 (48.2)12 854 (42.1)
 West21 280 (15.3)25 669 (18.5)4707 (15.4)6488 (21.2)
 Unknown2041 (1.5)3910 (2.8)310 (1.0)268 (0.9)
RA medications,† %
 Methotrexate86 895 (62.6)530 (0.4)20 230 (66.2)172 (0.6)
 Hydroxychloroquine42 288 (30.5)629 (0.5)11 252 (36.8)234 (0.8)
 Sulfasalazine11 545 (8.3)176 (0.1)2879 (9.4)69 (0.2)
 Leflunomide13 611 (9.8)60 (0.04)1892 (6.2)19 (0.06)
 b/tsDMARDs34 177 (24.6)265 (0.2)3070 (10.1)84 (0.3)
  • Values mean (SD) or n (%) of variables at the index date.

  • *Year entering the database during study window.

  • †RA medications received prior to, or on, the index date.

  • b/tsDMARDs, biologic or targeted synthetic disease-modifying anti-rheumatic drugs; RA, rheumatoid arthritis.